Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01373125 · ClinicalTrials.gov registry record
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
A clinical trial of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD), sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 99
- Enrollment target
- 1
- Study location
NCT01373125 is a study of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD) that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 99 participants, below the 520-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01373125, a study of Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD), has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose a study comparing the morphological and functional aspects of the neosquamous epithelium (NSE) after ablative therapy for dysplastic Barrett's esophagus (BE) to that of native squamous epithelium in normal controls as well as gastroesophageal reflux disease (GERD), non-Barrett's Esophagus (BE) subjects.
Conditions Studied
Study Locations (1)
North Carolina
- University of North Carolina Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01373125
The ClinicalTrials.gov registry entry for NCT01373125 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 520-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (81% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Barrett's Esophagus appearing as the primary indexed condition, and to 0 interventions.
NCT01373125 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01373125 about?
NCT01373125 is a clinical study titled "Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?". The investigators propose a study comparing the morphological and functional aspects of the neosquamous epithelium (NSE) after ablative therapy for dysplastic Barrett's esophagus (BE) to that of native squamous epithelium in normal controls as well as gastroesophageal reflux disease (GERD), non-Barr...
What is the current status of trial NCT01373125?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2011-06. Estimated completion is 2014-10.
What conditions does trial NCT01373125 study?
This clinical trial studies the following conditions: Barrett's Esophagus, Gastroesophageal Reflux Disease (GERD), Intestinal Metaplasia.
Who is sponsoring clinical trial NCT01373125?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01373125 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Barrett's Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Study for TCE Imaging of the Esophagus Using an OFDI Capsule With a Compact Imaging System
RECRUITING · NA
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Barrett's Esophagus Related Neoplasia (BERN) Project
RECRUITING
-
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING
-
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
RECRUITING
-
Navicam for Detection of Barrett's Esophagus
RECRUITING · NA
Explore more on PlainTrial
Barrett's Esophagus
All registered trials for this condition
Gastroesophageal Reflux Disease (GERD)
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.